Department of Radiology, Affiliated Jiangmen Hospital of Sun Yat-Sen University, Jiangmen, Guangdong, China.
School of Electronic Information and Automation, Guilin University of Aerospace Technology, Guilin, Guangxi, China.
J Magn Reson Imaging. 2019 Sep;50(3):847-857. doi: 10.1002/jmri.26688. Epub 2019 Feb 17.
Lymphovascular invasion (LVI) status facilitates the selection of optimal therapeutic strategy for breast cancer patients, but in clinical practice LVI status is determined in pathological specimens after resection.
To explore the use of dynamic contrast-enhanced (DCE)-magnetic resonance imaging (MRI)-based radiomics for preoperative prediction of LVI in invasive breast cancer.
Prospective.
Ninety training cohort patients (22 LVI-positive and 68 LVI-negative) and 59 validation cohort patients (22 LVI-positive and 37 LVI-negative) were enrolled.
FIELD STRENGTH/SEQUENCE: 1.5 T and 3.0 T, T -weighted DCE-MRI.
Axillary lymph node (ALN) status for each patient was evaluated based on MR images (defined as MRI ALN status), and DCE semiquantitative parameters of lesions were calculated. Radiomic features were extracted from the first postcontrast DCE-MRI. A radiomics signature was constructed in the training cohort with 10-fold cross-validation. The independent risk factors for LVI were identified and prediction models for LVI were developed. Their prediction performances and clinical usefulness were evaluated in the validation cohort.
Mann-Whitney U-test, chi-square test, kappa statistics, least absolute shrinkage and selection operator (LASSO) regression, logistic regression, receiver operating characteristic (ROC) analysis, DeLong test, and decision curve analysis (DCA).
Two radiomic features were selected to construct the radiomics signature. MRI ALN status (odds ratio, 10.452; P < 0.001) and the radiomics signature (odds ratio, 2.895; P = 0.031) were identified as independent risk factors for LVI. The value of the area under the curve (AUC) for a model combining both (0.763) was higher than that for MRI ALN status alone (0.665; P = 0.029) and similar to that for the radiomics signature (0.752; P = 0.857). DCA showed that the combined model added more net benefit than either feature alone.
The DCE-MRI-based radiomics signature in combination with MRI ALN status was effective in predicting the LVI status of patients with invasive breast cancer before surgery.
1 Technical Efficacy Stage: 2 J. Magn. Reson. Imaging 2019;50:847-857.
淋巴管侵犯(LVI)状态有助于为乳腺癌患者选择最佳的治疗策略,但在临床实践中,LVI 状态是在切除后的病理标本中确定的。
探讨基于动态对比增强(DCE)磁共振成像(MRI)的放射组学在术前预测浸润性乳腺癌 LVI 中的应用。
前瞻性。
90 例训练队列患者(22 例 LVI 阳性和 68 例 LVI 阴性)和 59 例验证队列患者(22 例 LVI 阳性和 37 例 LVI 阴性)。
磁场强度/序列:1.5T 和 3.0T,T1 加权 DCE-MRI。
基于 MR 图像评估每位患者的腋窝淋巴结(ALN)状态(定义为 MRI ALN 状态),并计算病变的 DCE 半定量参数。从第一次对比后 DCE-MRI 中提取放射组学特征。使用 10 倍交叉验证在训练队列中构建放射组学特征。确定 LVI 的独立危险因素,并开发 LVI 预测模型。在验证队列中评估其预测性能和临床实用性。
Mann-Whitney U 检验、卡方检验、kappa 统计、最小绝对值收缩和选择算子(LASSO)回归、逻辑回归、受试者工作特征(ROC)分析、DeLong 检验和决策曲线分析(DCA)。
选择了两个放射组学特征来构建放射组学特征。MRI ALN 状态(优势比,10.452;P<0.001)和放射组学特征(优势比,2.895;P=0.031)被确定为 LVI 的独立危险因素。结合两者的曲线下面积(AUC)值(0.763)高于 MRI ALN 状态(0.665;P=0.029),与放射组学特征相似(0.752;P=0.857)。DCA 显示,联合模型比单独使用任何特征都能带来更多的净收益。
基于 DCE-MRI 的放射组学特征与 MRI ALN 状态相结合,可有效预测术前浸润性乳腺癌患者的 LVI 状态。
1 技术功效阶段:2 J. Magn. Reson. Imaging 2019;50:847-857.